| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 73396 |
cy5.5-QS cy5.5荧光标记VEGF125-136小肽QS |
75 |
h |
2024-12-18 |
| 73397 |
THP-SS-PEG1-Boc CAS:1807503-88-3 |
76 |
zyl |
2024-12-18 |
| 73398 |
cas:132178-37-1，Propargyl-C1-NHS ester，2, 5-二氧代吡咯烷-1-基 戊-4-炔酸酯 |
62 |
kx |
2024-12-18 |
| 73399 |
CAS号为646502-53-6的MC-Val-Cit-PAB-MMAE |
83 |
WYQ |
2024-12-18 |
| 73400 |
DOTA-ECL1i 7-氨基酸CCR2结合肽[外环1变型(ECL1i)]偶联DOTA大环配体 |
84 |
h |
2024-12-18 |
| 73401 |
MC-EVCit-PAB-MMAE（CAS号：2873452-49-2） |
69 |
WYQ |
2024-12-18 |
| 73402 |
TPP-Lys(Acp-DOTA-Gd)-COOH Gd-DOTA-TPP 卟啉修饰DOTA钆配合物 |
66 |
h |
2024-12-18 |
| 73403 |
TPP-Lys(Acp-DOTA-Gd)-COOH Gd-DOTA-TPP 卟啉修饰DOTA钆配合物 |
70 |
h |
2024-12-18 |
| 73404 |
TPP-Lys(Acp-DOTA-Gd)-COOH Gd-DOTA-TPP 卟啉修饰DOTA钆配合物 |
70 |
h |
2024-12-18 |
| 73405 |
TPP-Lys(Acp-DOTA-Gd)-COOH Gd-DOTA-TPP 卟啉修饰DOTA钆配合物 |
65 |
h |
2024-12-18 |
| 73406 |
TPP-Lys(Acp-DOTA-Gd)-COOH Gd-DOTA-TPP 卟啉修饰DOTA钆配合物 |
68 |
h |
2024-12-18 |
| 73407 |
Ald-CH2-PEG2-CH2CO2 tBu ester，cas:2230956-95-1 |
73 |
zyl |
2024-12-18 |
| 73408 |
cas:796073-55-7，4-Methyl-4-(methyldisulfanyl)pentanoic acid，4-甲基-4-(甲基二硫烷基)戊酸 |
60 |
kx |
2024-12-18 |
| 73409 |
Ad-PG-FA 线性聚缩水甘油修饰叶酸靶向分子 |
79 |
h |
2024-12-18 |
| 73410 |
三嵌段共聚物PCL-PEEGE-PCL |
157 |
h |
2024-12-18 |
| 73411 |
炔基功能化的聚乙二醇(alkynyl-PEG) |
58 |
h |
2024-12-18 |
| 73412 |
cas:784105-33-5，Amino-PEG3-C2-acid，3-[2-[2-(2-氨基乙氧基)乙氧基]乙氧基]丙酸 |
78 |
kx |
2024-12-18 |
| 73413 |
Phthalamidoxy-PEG2-CH2-ald，cas:1415246-44-4 |
67 |
zyl |
2024-12-18 |
| 73414 |
甘草次酸偶联Gd-DOTA(GGD) |
58 |
h |
2024-12-18 |
| 73415 |
Fmoc-NH-PEG6-CH2COOH，cas:437655-96-4 |
57 |
zyl |
2024-12-18 |
| 73416 |
cas:557756-85-1，Fmoc-NH-PEG4-CH2CH2COOH，5,8,11,14-四氧杂-2-氮杂十七烷二酸1-(9H-芴-9-基甲基)酯 |
80 |
kx |
2024-12-18 |
| 73417 |
DOTA-3-酪氨酰基-奥曲肽 DOTA-TATE |
72 |
h |
2024-12-18 |
| 73418 |
DBCO-DOTA-Eu 叠氮功能化修饰OTA-Eu |
157 |
h |
2024-12-18 |
| 73419 |
HO-PEG10-CH2COOtBu |
73 |
zyl |
2024-12-18 |
| 73420 |
cas:1026987-94-9，DUPA(OtBu)-OH |
66 |
kx |
2024-12-18 |
| 73421 |
NOTA/DFO-MAL-Cys-MZHER2 亲和体Cys-MZHER2偶联螯合剂NOTA/DFO-MAL |
79 |
h |
2024-12-18 |
| 73422 |
N-DBCO-N-bis(PEG2-amide-PEG4-Val-Cit-PAB-MMAE) |
78 |
WYQ |
2024-12-18 |
| 73423 |
Propargyl-PEG2-CH2CO2-NHS ester，cas:2244145-13-7 |
75 |
zyl |
2024-12-18 |
| 73424 |
NHS ester-PEG4-Val-Cit-PAB-MMAE，（二苯并环辛炔N-羟基琥珀酰亚胺酯） |
162 |
WYQ |
2024-12-18 |
| 73425 |
1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸-1-柰丙氨酸-奥曲肽 DOTA-NOC |
71 |
h |
2024-12-18 |
| 73426 |
CAS号为1350456-56-2的Fmoc-Val-Cit-PAB-MMAE |
64 |
WYQ |
2024-12-18 |
| 73427 |
Azido-PEG3-CH2CO2Me，cas:1253389-31-9 |
64 |
zyl |
2024-12-18 |
| 73428 |
cas:60444-78-2，Ald-Ph-NHS ester，4-甲酰苯甲酸N-琥珀酰亚胺酯 |
120 |
kx |
2024-12-18 |
| 73429 |
荧光染料sulfo-Cy5.5-NHS酯 |
103 |
h |
2024-12-18 |
| 73430 |
DOTA-NVVRQ DOTA-TMTP1 双功能螯合剂DOTA偶联多肽TMTP1(NVVRQ) |
84 |
h |
2024-12-18 |
| 73431 |
CAS号为2353409-69-3的Mal-PEG8-Val-Cit-PAB-MMAE |
94 |
WYQ |
2024-12-18 |
| 73432 |
聚DOTA新型树枝状分子(PDOTA) |
91 |
h |
2024-12-18 |
| 73433 |
Anti-EGFR (cetuximab)-EDC/NHS-methotrexate |
142 |
kx |
2024-12-18 |
| 73434 |
CAS号为646502-53-6的MC-Val-Cit-PAB-MMAE |
128 |
WYQ |
2024-12-18 |
| 73435 |
介孔硅纳米粒子(MSNs) |
172 |
h |
2024-12-18 |
| 73436 |
DO3A-Ether-Rhein 10-{[6-(1,8-二羟基蒽醌-3-甲酰氨基)乙氧基乙基]氨基}羰酰甲基-1,4,7,10-四氮杂环十二烷-1,4,7-三乙酸 |
88 |
h |
2024-12-18 |
| 73437 |
MC-Val-Cit-PAB-MMAF（或简写为Vc-MMAF） |
91 |
WYQ |
2024-12-18 |
| 73438 |
Anti-CD33 (h2H12ec)-Mc-VC-SGD-1882， ADC试剂 |
103 |
kx |
2024-12-18 |
| 73439 |
FITC-cNGR 绿色荧光素FITC标记cNGR环状 |
91 |
h |
2024-12-18 |
| 73440 |
Azide-PEG3-Val-Cit-PAB-MMAF，叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
80 |
WYQ |
2024-12-18 |
齐岳微信公众号
官方微信
库存查询